Navigation Links
Alba Therapeutics Corporation and Shire plc Enter Into $325 Million ex-US, ex-Japan Licensing Agreement to Develop and Commercialize AT-1001
Date:12/14/2007

BALTIMORE, Dec. 14 /PRNewswire/ -- Alba Therapeutics Corporation announced today that it has entered into a strategic collaboration with Shire plc (LSE: SHP, Nasdaq: SHPGY, TSX: SHQ), to jointly develop AT-1001, Alba's lead inhibitor of barrier dysfunction in various gastrointestinal ("GI") disorders. Shire will receive rights to commercialize all forms of AT-1001 outside of the United States and Japan. Alba will retain all rights to commercialize AT-1001 in the United States and Japan.

Under the terms of the collaboration, Alba will receive an initial, non- refundable licensing payment of US$ 25 million. Joint development costs toward global approval of AT-1001 will be shared 50/50 after the completion of two Phase 2 studies for Celiac disease. Alba is eligible to receive over US$ 80 million if certain clinical, regulatory and launch milestones are met for certain GI indications. Additional milestone payments totaling over US$ 40 million per indication will also be payable to Alba if the Collaboration is expanded beyond GI indications. Alba is also eligible to receive up to US$ 220 million in sales-based milestones, as well as tiered royalties. Not including royalties and cost sharing, the deal is valued at over US$ 325 million if all milestones are achieved.

Dr. Blake M. Paterson, Alba's President & CEO said:

"We are pleased to enter into this partnership with Shire, which leverages the unique experience and expertise of both companies in developing therapies for GI disorders. The combination of Alba's barrier function technology and autoimmune development capabilities with Shire's proven track record in GI drug development and commercialization will greatly enhance our efforts to bring these novel therapies to patients."

Matthew Emmens, Shire's CEO said:

"Alba's products have the potential to be an excellent addition to our current gastrointestinal business. This technology should provide significant benefit to patients w
'/>"/>

SOURCE Alba Therapeutics Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
3. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
4. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
5. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
6. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
7. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
8. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
9. Amsterdam Molecular Therapeutics Reports Half Year Results 2007
10. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
11. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... , Sept. 17, 2014  MiMedx Group, Inc. ... processor and marketer of patent protected regenerative biomaterials ... today the publication of another peer-reviewed clinical study.    ... A Multi-center Randomized Controlled Clinical Trial Evaluating the ... Membrane Allografts and Multi-layer Compression Therapy vs. Multi-layer ...
(Date:9/17/2014)... Terracon Corporation has announced the introduction of a ... This addition to the company’s industry-leading line of custom ... available in 125 or 250 gallon capacities. It ... or less. , The new pre-engineered TerraPure tank offers ... TerraPure tank line – plus quick turnaround. An ...
(Date:9/17/2014)... Calif. , Sept. 17, 2014 ... molecular diagnostics company pioneering the field of molecular cytology, ... chief operating officer. Mr. Hall joined Veracyte ... company,s commercial entry into endocrinology. Since 2012, he has ... well as managed care and billing functions. As chief ...
(Date:9/17/2014)... , September 17, 2014 ... of action from a truly novel class ... MGB Biopharma, a biopharmaceutical company developing ... today that it has secured £4.0m ($6.4m) ... antibacterial, MGB-BP-3, against a range of Gram-positive ...
Breaking Biology Technology:MiMedx Multi-Center Randomized, Controlled VLU Clinical Study Published In Peer-Reviewed Journal 2MiMedx Multi-Center Randomized, Controlled VLU Clinical Study Published In Peer-Reviewed Journal 3MiMedx Multi-Center Randomized, Controlled VLU Clinical Study Published In Peer-Reviewed Journal 4Terracon Introduces Pre-Engineered TerraPure® Tank for Ultrapure Water Applications 2Veracyte, Inc. Announces Promotion of Christopher M. Hall To Chief Operating Officer 2Veracyte, Inc. Announces Promotion of Christopher M. Hall To Chief Operating Officer 3Veracyte, Inc. Announces Promotion of Christopher M. Hall To Chief Operating Officer 4MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 2MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 3MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 4MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 5MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 6MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 7
... Allows Accurate Marketing Claims Designed with Input from,Entire ... nation,s leading livestock,cloning companies announced today a tracking ... allow food companies to identify cloned animals,when they ... program was developed through extensive cooperative discussions,over the ...
... MATEO, Calif., Dec. 19 BioForm Medical,Inc. (Nasdaq: ... will present a company overview at the upcoming 26th ... BioForm,Medical,s presentation will take place on Monday, January 7th, ... Westin St. Francis Hotel in San Francisco,CA., A ...
... Holdings, Inc. (OTC,Bulletin Board: HTWO) announced today that ... Mirant Energy Trading LLC, a subsidiary of Mirant ... biofuel technology in utility,scale power generation applications., ... biofuel for a gas,turbine test program that will ...
Cached Biology Technology:Top U.S. Cloning Companies Announce New System to Track Cloned Livestock 2BioForm Medical to Present at the 2008 JPMorgan Healthcare Conference on January 7, 2008 2H2Diesel Holdings Announces Test Burn Agreement With Mirant Corp. 2H2Diesel Holdings Announces Test Burn Agreement With Mirant Corp. 3
(Date:9/16/2014)... fall marks a new school year, a new football ... Space Station. In September, SpaceX,s Dragon spacecraft is scheduled ... and investigations as part of the company,s fourth contracted ... will be the third suite of research investigations sponsored ... Space (CASIS). With the role of managing the U.S. ...
(Date:9/16/2014)... (KXL) would likely increase oil sands extraction, according to ... non-profit organization Near Zero. The results are detailed in ... both supporters and opponents of the pipeline. ... to significantly higher greenhouse gas emissions, with the exact ... "This report examines three main scenarios discussed by participants ...
(Date:9/16/2014)... votes for independence later this week, its Government could ... that fracking is necessary, research has revealed. , The ... public perception of shale gas extraction in the UK ... north of the border are the least supportive of ... in the University,s School of Geography, said: "The clear ...
Breaking Biology News(10 mins):CASIS research set for launch aboard SpaceX mission to space station 2CASIS research set for launch aboard SpaceX mission to space station 3Keystone XL would likely raise oil sands production and greenhouse gas emissions 2Scottish people most sceptical on fracking, survey shows 2Scottish people most sceptical on fracking, survey shows 3
... Medicine and University of Crete School of Medicine researchers ... a molecular mechanism that dynamically alters the strength of ... the development of drug therapies for the cognitive deficits ... bipolar disorder, or attention deficit hyperactivity disorder (ADHD). ...
... novel gene mutation that causes X-linked mental retardation for ... to an article to be published electronically on Tuesday, ... Genetics. , Investigators F. Lucy Raymond (Cambridge Institute ... Patrick S. Tarpey (Wellcome Trust Sanger Institute, Hixton, UK) ...
... the University of California, San Diego and the University ... of estimated plant species richness. Covering several hundred thousand ... most extensive map of the distribution of biodiversity on ... study published in this week's early online issue of ...
Cached Biology News:Brain networks strengthened by closing ion channels 2Brain networks strengthened by closing ion channels 3Severe mental retardation gene mutation identified 2Biologists produce global map of plant biodiversity 2
... to the maintenance of appropriate levels ... important and diverse as those involved ... stress response, antigen presentation, modulation of ... cell cycle regulation, transcription, and signalling ...
... includes 1. Scanning of gel(s) 2. ... tryptic in-gel digestion and peptide extraction ... 5. Acquisition of PMF (Peptide Mass ... TOF/TOF) 6. Acquisition of PFF (Peptide ...
... The Vibratome Company has joined forces with ... the Vibratome 411301 Tissue Chopper. This tissue ... sections of tissue for metabolic experiments and ... irregular specimens available at biopsy or from ...
... The ProteinChip Antibody ... assay development and optimization ... evaluate antibody-antigen interactions. This ... and differentiation of multiple ...
Biology Products: